Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Nov 14, 2023 2:20pm
331 Views
Post# 35734997

Institutional investor

Institutional investor

So, what we know vs what we think we know.
1. Anison did/ was the instutional player that bought $15 million + of Onc shares.
2. They are a mutual fund company.
3. They have a broad range of focus, not limited to short positions.
4. Their prime focus is long & long term strategy.

All clearly stated on their web site.

5. They also have a substantial opportunity to cash in on warrants if/ when the price is above much higher than now. I can't recall the exact numbers. Higher none the less.

Now boys & girls.......many have picked up the " shorting" ball & ran with it.
Really?

Mutual funds are " rewarded" on their ability to make $$$. That being with a very long term focus.
unless you are from an alternative universe, shorting one's holdings ( there- by lowing the value of the fund", makes zero mathematical sense what so ever.
Save your rhetoric & stick to the facts.

Yes the PanCan blackout is a major blow. More delays & more confusion.
The Anison $15 million in shares?
We know they bought them. & still own.
beyond that 100% speculation. The shorting thought? Makes zero sense what so ever.

 

<< Previous
Bullboard Posts
Next >>